GlassScriptPhysician profile
Fady S Boules
NPI 1639541022
$6,548.96
in general payments reported to CMS, 2019-2025
24 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $987 · 2022: $1,529 · 2023: $1,109 · 2024: $1,415 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $964.78 | 2022-2024 | Dovato, Apretude |
| Abbvie INC. | $920.28 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $883.76 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $663.98 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $477.78 | 2021-2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $421.76 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.10 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $352.81 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $283.41 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $272.83 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $229.85 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $144.14 | 2021-2023 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $142.66 | 2021-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $141.31 | 2023 | |
| Amgen INC. | $107.69 | 2024 | Tavneos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.11 | 2022 | |
| Lundbeck LLC | $27.57 | 2021-2025 | Rexulti |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Indivior INC. | $21.16 | 2022 | |
| Bausch Health US, LLC | $20.94 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.18 | 2022 | |
| Brainsway USA INC | $13.43 | 2023 | |
| Medtronic, INC. | $13.29 | 2022 | |
| Corium, LLC | $10.64 | 2023-2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Boules listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.